336191-16-3

Basic information

• Product Name: tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate
• Synonyms: tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate;8-Benzyl-2,8-diaza-spiro[4.5]decane-2-carboxylic acid tert-butyl ester;2,8-Diazaspiro[4.5]decane-2-carboxylic acid, 8-(phenylMethyl)-, 1,1-diMethylethyl ester
• CAS NO: 336191-16-3
• Molecular Formula: C₂₀H₃₀N₂O₂
• Molecular Weight: 344.496
• Mol File: 336191-16-3.mol

Chemical Properties

• Boiling Point: 428.9°C at 760 mmHg
• Flash Point: 213.2°C
• Appearance: /
• Density: 1.10
• Vapor Pressure: 1.47E-07mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate(336191-16-3)
• EPA Substance Registry System: tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate(336191-16-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 336191-16-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate is used as a potential pharmaceutical candidate due to its unique structure and properties. tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate's complex chemical composition, including the spirocyclic ring system and the carboxylic ester group, may contribute to its potential as a therapeutic agent. The steric hindrance provided by the tert-butyl substituent could also play a role in its interaction with biological targets, although further research is needed to determine its specific applications and efficacy.
Used in Drug Development Research:
In the field of drug development research, Tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate serves as a valuable compound for exploring new chemical spaces and potential therapeutic targets. Its unique structural features may offer insights into the design of novel drugs with improved pharmacological profiles. tert-Butyl 8-benzyl-2,8-diazaspiro[4.5]decane-2-carboxylate's potential biological activities and interactions with biological systems are areas of active investigation, with the aim of identifying its role in various therapeutic applications.

InChI:InChI=1/C20H30N2O2/c1-19(2,3)24-18(23)22-14-11-20(16-22)9-12-21(13-10-20)15-17-7-5-4-6-8-17/h4-8H,9-16H2,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 336191-15-2 8-benzyl-2,8-diazaspiro[4.5]decane 
• 1463-52-1 ethyl 2-(1-benzylpiperidin-4-ylidene)-2-cyanoacetate 
• 336191-13-0 8-benzyl-2-(4-methoxy-benzyl)-2,8-diaza-spiro[4.5]decane-1,3-dione 
• 336191-14-1 8-benzyl-2-(4-methoxybenzyl)-2,8-diazaspiro[4.5]decane 
• 86945-27-9 1-benzyl-4-cyanomethylpiperidine-4-carbonitrile 
• 40117-92-8 1-benzyl-4-carboxymethyl-piperidine-4-carboxylic acid 

Downstream Products

• 1001054-52-9 8-cyclobutyl-2,8-diaza-spiro[4.5]decane-2-carboxylic acid tert-butyl ester 
• 959640-90-5 8-cyclobutyl-2,8-diaza-spiro[4.5]decane 
• 336191-17-4 tert-butyl 2,8-diazaspiro[4.5]decane-2-carboxylate 

Relevant articles and documents

SUBSTITUTED AZASPIRO DERIVATIVES

Substituted azaspiro derivatives of the Formula:are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

SPIROCYCLIC SULFONAMIDES AND RELATED COMPOUNDS

Spirocyclic sulfonamides and related compounds of Formula 1 are provided : (Formula (I)): in which the variables are as described herein. Such compounds may be used to modulate bradykinin receptor activity in vivo or in vitro, and are particularly useful

2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF

The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.

Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation

Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes

The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the spiro structures as central template for nonpeptide RGD mimics.